IDO1 and neoplasm: Finally, when Monjazeb et al. [46] tested the “triple therapy” in canines with spontaneous metastatic melanomas and sarcomas, they found a reduced tumor burden and improved survival (vs historical controls), suggesting that a canine model could be useful in the future for testing IDO-inhibiting strategies in humans with melanoma and sarcoma [46].